Aspirin과 Prednisolone 병용투여시의 항염증 및 해열작용에 관한 연구

Effects of Concurrent Administration of Aspirin and Prednisolone on the Anti-inflammatory and Antipyretic Activities in Rats

  • 발행 : 1978.09.01

초록

Aspirin and prednisolone have been used alone or in combination in the treatment of rheumatic diseases. We have investigated the significance of the difference of the anti-inflammatory and antipyretic activities between single and concurrent administration of aspirin and prednisolone in rats by using carrageenan as a phlogistic agent and brewer's yeast as a fever inducing agent. When prednisolone (9mg/kg) and aspirin (24mg/kg) were administered orally alone or in combination, both of the concurrent and single adminstration inhibited highly significantly the swelling of rat paw and the concurrent adminstraiton of aspirin and prednisolone showed the significantly higher inhibitory effects than aspirin single adminstration did, whereas there were not any significant differences between the prednisolone single adminstration and combined adminstration. The combined drug of aspirin and prednisolone marketed in Korea contains 148mg of aspirin and 1.15mg of prednisolone in a tablet. Therefore, we examined the anti-inflammatory and antipyretic activities of aspirin (150mg/kg), prednisolone (1mg/kg) and their combination. In anti-inflammatory effects, both of the concurrent and single administration inhibited higly significantly the swelling of rat paw, and the concurrent adminstration exhibited the significantly higher inhibitory effects than aspirin or prednisolon alone did. In antipyretic effects both of the concurrent and the single adminstration reduced significantly the brewer's yeast-induced fever. The effect of concurrent administration was greater than that of prednisolone single adminstration, whereas the effect of aspirin single adminstration was similar to that of combination. The results suggest that the anti-inflammatory and antipyretic effects are intensified by the concurrent adminstration of aspirin and prednisolone, but the antipyretic effects of enough doses of aspirin (150mg/kg) is comparable to that of the combination preparation.

키워드

참고문헌

  1. J. Pharm. Pharmacol. v.14 J.M.Hrris;P.S.J.Spencer
  2. Proc. Soc. Exp. Biol. Med. v.111 C.A.Winter;E.A.Risley;G.W.Nuss
  3. J. Pharmacol. Exp. Ther. v.150 C.G. Van Arman;A.J.Begang;L.M.Miller;H.H.Pless
  4. Arzneim. Forsch. (Drug Res.) v.1 G.Wilhelmi;R.D.Domenjoz
  5. Nature v.176 A.Cerletti;E.Rothlin
  6. Canad. J. Biochem. Physiol. v.33 V.W.Adamkiewcz;W.B.Rice;J.D.McColl
  7. Nature v.179 G.A.H.Buttle;P.F.D'Arcy;E.M.Howard;D.N.Kellett
  8. J. Pharmacol. v.24 H.Tanaka;A.Kiyohara;H.Orima;Y.Suzuki;K.Takagi;S.Okake;Japha
  9. J. Pharmacol. Exp. Ther. v.172 K.F.Swingle;T.J.Grant;L.W.Jaques;D.C.Kvam
  10. Ohio State Medical Journal v.52 M.M.Szues;V.Holonko;K.M.Forster;Malagan
  11. Reumatismo v.8 A.Robechi;V.Danea;G.Marrazzi
  12. Reumatismo v.9 R.Scalabrio;G.Pasquariello
  13. Rev. Brasil. Med. v.22 O.R.Santos;J.Houli
  14. J. Pharmacol. Exp. Ther. v.187 C.G. Van Arman;G.W.Nuss;E.A.Risley
  15. Arzneim. Forch. (Drug Res.) v.25 C.J.E.Niemegeers;F.M.Lenaerts;P.A.J.Janssen
  16. J. Pharmacol. Exp. Ther. v.155 E.M.Glenn;B.J.Bowman;W.Kooyers;T.Koslowske;M.L.Myers
  17. Arch int. Pharmacodyn. v.175 R.W.Shanahan
  18. J. Pharm. Pharmacol. v.16 C.J.E.Niemegeers;F.J.Verbruggen;P.A.J.Janssen
  19. J. Canad. Chem. v.33 D.B.Smith;A.N.O'Neill;A.S.Perlin
  20. Federation Proc. v.21 E.L.McCandless
  21. J. Pharmacol. Exp. Ther. v.166 R.Vinegar;W.Schreiber;R.Hugo
  22. Anti-inflammatory Agents (Chemistry and Pharmacology) v.2 K.F.Swingle
  23. Pharmacologist v.13 C.G. Van Arman;E.A.Risley;P.T.Kling
  24. J. Pharm. Sci. v.53 G.Levy;R.H.Reuning
  25. Mol. Pharmacol. v.2 R.P.Maickel;M.T.Bush;W.R.Jondorf;F.P.Miller;J.R.Gillette
  26. Mol. Pharmacol. v.4 T.R.Tephly;G.J.Mannering
  27. Antibiot. Chemother. v.3 A.Hemming;A.Kuzell
  28. Arzneim Forsch. v.18 Schoger
  29. Postgrad. Med. v.44 C.J.Smyth
  30. Biochem. Pharmacol. v.17 no.Suppl E.M.Glenn;B.J.Bowman;T.C.Koslowske
  31. J.A.M.A. v.143 P.F.A.Hoeger;G.H.Glaser
  32. Ann. rheum. Dis. v.18 M.J.H.Smith
  33. Brit. Med. J. v.2 J.B.Cochran
  34. Brit. Med. J. v.1 J.B.Cochran
  35. Proc. Soc. Exp. Biol. v.75 D.J.Ingle
  36. Biochem. J. v.52 M.J.H.Smith
  37. Biochem. J. v.51 M.J.H.Smith;B.W.Meada;J.Bornstein
  38. Aust. Ann. Med. v.6 B.S.Hetzel;R.Williams;H.Lander
  39. Brit. Med. J. v.2 J.Reid;A.I. Mac Dougall;M.M.Andrews